Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab

Published:2017-07-07 Issue:1 Volume:36 Page:144-149
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Verriere B.¹^ORCID,Gastaud L.²,Chamorey E.³,Peyrade F.²,Deletie E.¹,Bouredji K.⁴,Quinsat D.⁵,Schiappa R.³,Thyss A.²,Re D.²⁴

Affiliation:

1. Pharmacy department; Antibes Hospital; Antibes France

2. Oncology department; Anticancer Center Antoine Lacassagne; Nice France

3. Biostatistics and epidemiology department; Anticancer Center Antoine Lacassagne; Nice France

4. Oncology and hemato oncology department; Antibes Hospital; Antibes France

5. Internal Medicine department; Antibes Hospital; Antibes France

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hon.2458/fullpdf

Reference35 articles.

1. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial;Rummel;Lancet,2013

2. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial;Rummel;Lancet Oncol,2016

3. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study;Flinn;Blood,2014

4. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial;Eichhorst;Lancet Oncol,2016

5. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma;Rummel;J Clin Oncol,2005

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Update on the Incidence, Risk Factors and Mechanisms of Rituximab- Associated Neutropenia;Archives of Medical Science;2022-09-15

2. Late-onset toxicities of monoclonal antibodies in cancer patients;Immunotherapy;2022-09

3. Case Report: High Doses of Intravenous Immunoglobulins as a Successful Treatment for Late Onset Immune Agranulocytosis After Rituximab Plus Bendamustine;Frontiers in Immunology;2022-01-10

4. Late onset neutropenia after rituximab and obinutuzumab treatment – characteristics of a class-effect toxicity;Leukemia & Lymphoma;2021-07-21

5. An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma;OncoImmunology;2021-01-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3